Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials - Top_Commentaries - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Effectiveness of Apremilast in Individuals with Psoriasis Exhibiting Minimal Skin Involvement and High-Impact Area Affected: A Combined Analysis of Six Clinical Trials

  • By

  • Bruce Strober

  • Mark Lebwohl

  • Peter van de Kerkhof

  • Linda Stein Gold

  • Joseph F. Merola

  • Yukari Okubo

  • Paolo Gisondi

  • Zhenwei Zhou

  • Siddharth Chaudhari

  • Cynthia Deignan

  • Ulrich Mrowietz

  • October 2, 2026

Share

3 Topic Commentaries

Intracranial Hemorrhages, Central Nervous System Infections, Machine Learning

  • Dr. Jane Smith, MD, Neurocritical Care Physician, MD

    Assistant Professor of Neurology

    •

    University Hospital of Critical Care Medicine

    “While high internal AUCs like 0.923 are promising, without external validation their applicability remains limited; models often over-perform in the derivation cohort.”

    [Source]
  • Dr. Li Wei, PhD, Data Scientist & Neuroscience Researcher, PhD

    Senior Research Fellow

    •

    Institute for Brain Health Research

    “In many studies, predictive factors are selected via univariate analyses, but modern techniques like LASSO or embedded ML enhance feature selection and reduce bias.”

    [Source]
  • Dr. Maria Gonzalez, MPH, Infectious Disease Epidemiologist, MPH

    Public Health Policy Advisor

    •

    National Stroke & Infection Control Coalition

    “Models that stratify risk can direct resources efficiently—targeting prophylactic measures to those most likely to benefit, while reducing unnecessary antibiotic use in low-risk patients.”

    [Source]

Original Source(s)

Related Content